Articles related to BIOSIMILARS

US prescription drug expenditures reached $915.2 billion in 2025, with utilization growth rather than price increases accounting for the majority of the 12.7% rise, and clinic-sector spending projected to outpace hospital spending by a factor of three in 2026.

Comprehensive data package, including structural and functional analytical data, clinical pharmacokinetic data, and a comparative clinical study demonstrating that Bildyos and Bilprevda are highly similar to and have no clinically meaningful differences from their reference products.

PBMs’ vertical integration allows them to dictate cancer treatment decisions, from drug selection to delivery methods, potentially compromising patient care and increasing costs.

As pharmacists, it’s crucial to note that, although these changes in FDA guidelines may not directly impact your practice, they signify a shift in how biosimilars will be identified moving forward. This could potentially influence how you advise patients about these products.

Explore the FDA-approved Tyruko, a biosimilar to Tysabri, which has shown comparable safety and efficacy in phase 3 clinical trials for treating relapsing forms of MS.

Discover how the 340B Drug Pricing Program influences prescription trends toward higher-cost biologics over biosimilars, and what this means for cost-effective healthcare.